Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.55 |
| ▸ | CA1 | P00915 | 10/20 | 0.55 |
| ▸ | CA2 | P00918 | 10/20 | 0.55 |
| ▸ | CA9 | Q16790 | 10/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038926 | 0.87 | LMNA (0.64) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL21708008 | 0.85 | KDM1A (0.67) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL21708021 | 0.84 | MAPT (0.68) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL3044989 | 0.83 | L3MBTL1 (0.60) | CYP1A2CYP2C19EGFRLMNANPSR1 | |
| SCHEMBL5035870 | 0.83 | LMNA (0.71) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL2831045 | 0.83 | L3MBTL1 (0.62) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL10464406 | 0.81 | MAPT (0.65) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL5041112 | 0.81 | EGFR (0.73) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL4789312 | 0.81 | SMN1; SMN2 (0.69) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL21708010 | 0.81 | GAA (0.64) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CA12 4051/4885CA1 4072/4885CA2 2164/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | CA12 374/4885CA1 551/4885CA2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.